Performance of the VERSANT® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes

FEMS Immunology and Medical Microbiology

Volumn 39, Issue 2, 2003, Pages 119-124

  Derdelinckx, Inge ^a   Van Laethem, Kristel ^a   Maes, Bart ^a   Schrooten, Yoeri ^a   De Schouwer, Kirsten ^a   De Wit, Stéphane ^b   Fransen, Katrien ^c   García Ribas, Sergio ^c   Moutschen, Michel ^d   Vaira, Dolores ^d   Zissis, Georges ^b   Van Ranst, Marc ^a   Van Wijngaerden, Eric ^a   Vandamme, Anne Mieke ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Human immunodeficiency virus type 1; Line probe assay; Resistance testing; Subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BELGIUM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; CLASSIFICATION; COMPARATIVE STUDY; DNA SEQUENCE; DRUG EFFECT; EVALUATION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MUTATION; NUCLEIC ACID HYBRIDIZATION; VIROLOGY;

ANTI-HIV AGENTS; BELGIUM; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; NUCLEIC ACID HYBRIDIZATION; SEQUENCE ANALYSIS, DNA;

EID: 0242558933     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00240-2     Document Type: Article

References (21)

1. Yeni P., Hammer S.M., Carpenter C.C.J., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schlechter M., Schooley R.T., Thompson M.A., Vella S., Volberding P.A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:2002;222-235.
2. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel [see comments]. JAMA. 283:2000;2417-2426.
3. The Euro Guidelines Group for HIV resistance (2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15, 309-320.
4. Vandamme A.-M., Houyez F., Bànhegyi D., Clotet B., De Schrijver G., De Smet K.A.L., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Holtzer C., Larder B., Pillay D., Race E., Schmit J.-C., Schuurman R., Shulse E., Sönnerborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir. Ther. 6:2001;21-40.
5. Rapport 2002 sous la direction du Professeur J.F. Delfraissy (2002) Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts. Médecine-Sciences, Flammarion, Paris.
6. Van Laethem K., Van Vaerenbergh K., Schmit J.-C., Sprecher S., Hermans P., De Vroey V., Schuurman R., Harrer T., Witvrouw M., Van Wijngaerden E., Stuyver L., Van Ranst M., Desmyter J., De Clercq E., Vandamme A.-M. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. JAIDS. 22:1999;107-118.
7. Stuyver L., Wyseur A., Rombout A., Louwagie J., Scarcez T., Verhofstede C., Rimland D., Schinazi R.F., Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:1997;284-291.
8. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., Hellmann N.S., Chesney M., Busch M.P., Kahn J.O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 288:2002;181-188.
9. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:2002;385-394.
10. Snoeck J., Van Dooren S., Van Laethem K., Derdelinckx I., Van Wijngaerden E., De Clercq E., Vandamme A.-M. Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. Virus Res. 85:2002;95-108.
11. Fontaine E., Riva C., Peeters M., Schmit J.-C., Delaporte E., Van Laethem K., Van Vaerenbergh K., Snoeck J., Van Wijngaerden E., De Clercq E., Van Ranst M., Vandamme A.-M. Evaluation of two commercial kits for the detection of genotypic drug-resistance on a panel of human immunodeficiency virus type-1 subtypes A-J. JAIDS. 28:2001;254-258.
12. Jenny-Avital E.R., Beatrice S.T. Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin. Infect. Dis. 32:2001;1227-1230.
13. Fransen K., Buve A., Nkengasong J.N., Laga M., van der Groen G. Longstanding presence of non-B subtypes in Belgians. Lancet. 347:1996;1403.
14. Vandamme, A.-M., Witvrouw, M., Pannecouque, C., Balzarini, J., Van Laethem, K., Schmit, J.-C., Desmyter, J. and De Clercq, E. (2000) Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Methods in Molecular Medicine (Kinchington, D. and Schinazi, R.F., Eds.), pp. 223-258. Humana Press Inc., Totowa, New York.
15. Descamps D., Calvez V., Collin G., Cécille G., Apetrei C., Damond F., Katlama C., Matheron S., Huraux J.-M., Brun-Vézinet F. Line Probe Assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis. J. Clin. Microbiol. 36:1998;2143-2145.
16. Schmit J.-C., Ruiz L., Stuyver L., Van Laethem K., Vanderlinden I., Puig T., Rossau R., Desmyter J., De Clercq E., Clotet B., Vandamme A.-M. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance. J. Virol. Methods. 73:1998;82.
17. Puchhammer-Stöckl E., Schmied B., Mandl C.W., Vetter N., Heinz F.X. Comparison of Line Probe Assay (LiPA) and sequence analysis for detection of HIV-1 drug resistance. J. Med. Virol. 57:1999;283-289.
18. Koch N., Yahi N., Colson P., Fantini J., Tamalet C. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. J. Virol. Methods. 80:1999;25-31.
19. Servais J., Lambert C., Fontaine E., Plesseria J.M., Robert I., Arendt V., Staub T., Schneider F., Hemmer R., Burtonboy G., Schmit J.C. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J. Clin. Microbiol. 39:2001;454-459.
20. Stürmer M., Morgenstern B., Staszewski S., Doerr H.W. Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based on genotyping systems. J. Clin. Virol. 25:2002;S65-S72.
21. Louwagie J., McCutchan F.E., Peeters M., Brennan T.P., Sanders-Buell E., Eddy G.A., van der Groen G., Fransen K., Gershy-Damet G.-M., Deleys R., Burke D.S. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 7:1993;769-780.